41 results on '"Horowitz, Netanel A."'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
4. A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis
5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
6. Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model.
7. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas
8. 2654. International Multi-Center Study Comparing the Effect of Obinutuzumab or Rituximab Treatment in Hematological Patients on COVID-19 Outcomes During the Omicron Surge
9. Hematopoietic Transplantation and Cellular Therapy in Acute Lymphoblastic Leukemia
10. Flow-cytometry Assessment of DNA content Analysis and Immunophenotyping of Immune-cells in Lymph-node-specimens as Potential Diagnostic Signature of Aggressiveness in B-Non-Hodgkin Lymphomas
11. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
12. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma
13. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
14. Working from home made possible in a health care facility - the experience of a tertiary hospital during the first Covid-19 wave
15. A higher BMI is positively associated with advanced neck lymphoma at diagnosis
16. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression
17. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review
18. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era
19. Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
20. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
21. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
22. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study
23. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
24. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
25. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.
26. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression.
27. Revisiting SARS-CoV-2 environmental contamination by patients with COVID-19: The Omicron variant does not differ from previous strains
28. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.
29. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
30. Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial
31. Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
32. Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
33. Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
34. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
35. Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
36. Continuous Remote Patient Monitoring Shows Early Cardiovascular Changes in COVID-19 Patients
37. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses
38. Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses
39. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
40. Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study
41. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.